The goals of this new R21 grant are to determine a) how a novel Chlamydia-specific transcription factor designated GrgA controls chlamydial growth by regulating gene expression, and b) whether GrgA is a target for benzylidene acylhydrazides, which have been recognized as novel antichlamydials. Chlamydia is an obligate intracellular bacterium with a unique developmental cycle. It is the most common sexually transmitted bacterial pathogen. Sexually transmitted chlamydial infection often leads to infertility, abortion, ectopic pregnancy and pelvic inflammatory disease. Transcription not only controls chlamydial growth and pathogenicity, but also represents an effective therapeutic target for chlamydial infections. We have identified a highly novel transcription factor that we call GrgA. Encoded by chlamydiae only, GrgA activates transcription in vitro from promoters that require the primary or housekeeping ? factor (a subunit of the RNAP polymerase) designated ?66 by interacting with the non-conserved region of the ? factor. Further evidence support the hypothesis that GrgA plays a critical role in the regulation of chlamydial growth, and is potentially a target for antichlamydials with therapeutic and prophylactic potentials. We propose two Specific Aims to test this hypothesis.
In Aim 1, we will identify the regulon of GrgA, and determine how alterations in the GrgA activity affect the transcriptome expression, and growth and developmental properties in Chlamydia.
In Aim 2, we will determine the role of GrgA in chlamydial growth inhibition by benzylidene acylhydrazides, a new group of antichlamydials with undetectable toxicity to host cells and beneficial lactobacilli that dominate the vaginal microbiome of healthy, reproductive-age women. We anticipate three significant outcomes from this study: a) this research will yield insights into transcription regulation in chlamydia; b) we may confirm that GrgA is a target of benzylidene acylhydrazides; and c) with an elucidation of the drug targeting mechanism, benzylidene acylhydrazides could prove valuable as chemical probes for studying chlamydial biology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI122034-01
Application #
9018300
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Hiltke, Thomas J
Project Start
2016-04-01
Project End
2018-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Rbhs-Robert Wood Johnson Medical School
Department
Pharmacology
Type
Schools of Medicine
DUNS #
078795875
City
Piscataway
State
NJ
Country
United States
Zip Code
Fan, Huizhou; Zhong, Guangming (2018) 2017: beginning of a new era for Chlamydia research in China and the rest of the world. Microbes Infect 20:5-8
Desai, Malhar; Wurihan, Wurihan; Di, Rong et al. (2018) A role for GrgA in regulation of ?28-dependent transcription in the obligate intracellular bacterial pathogen Chlamydia trachomatis. J Bacteriol :
Li, Jian Lin; Yang, Ningjing; Huang, Lei et al. (2018) Pyocyanin Inhibits Chlamydia Infection by Disabling Infectivity of the Elementary Body and Disrupting Intracellular Growth. Antimicrob Agents Chemother 62:
Li, Jian Lin; Chen, Dandan; Huang, Lei et al. (2017) Antichlamydial Dimeric Indole Derivatives from Marine Actinomycete Rubrobacter radiotolerans. Planta Med 83:805-811
Zhang, Huirong; Kunadia, Anuj; Lin, Yingfu et al. (2017) Identification of a strong and specific antichlamydial N-acylhydrazone. PLoS One 12:e0185783